• If you are wondering whether Thermo Fisher Scientific at around US$472.95 is genuinely good value or just pricing in high expectations, the starting point is to look closely at what the current valuation is really saying.
• The stock has returned 1.4% over the last 7 days, a 3.1% decline over the last 30 days, a 20.2% decline year to date, but a 16.4% gain over the last year, which gives a mixed picture of sentiment and risk appetite over different time frames.
• Recent headlines have focused on Thermo Fisher Scientific's role across healthcare tools, diagnostics and lab equipment, which keeps attention on how its products fit into long term spending by its customers. This context helps explain why the stock can show both shorter term setbacks and longer term strength as investors reassess what they are willing to pay.
• On Simply Wall St's 6 point valuation framework, Thermo Fisher Scientific currently scores a full 6 out of 6. The next step is a closer look at how different valuation methods line up on the stock, and how a broader, story based view can sometimes give an even clearer picture of value.

Approach 1: Thermo Fisher Scientific Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those cash flows back into today’s dollars. The idea is simple: if you know what cash you expect to receive and what return you require, you can work out what that stream is worth right now.

For Thermo Fisher Scientific, the model used is a 2 stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $6.8b. Analyst and extrapolated projections suggest free cash flow reaching about $11.9b in 2030, with detailed annual forecasts between 2026 and 2035 that Simply Wall St discounts back to today using its required return assumptions.

Pulling all those discounted cash flows together, the model arrives at an estimated intrinsic value of about $642.58 per share. Against the current share price of around $472.95, this implies roughly a 26.4% discount, which points to the stock trading below this DCF estimate of value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Thermo Fisher Scientific is undervalued by 26.4%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Thermo Fisher Scientific Price vs Earnings

For a profitable company like Thermo Fisher Scientific, the P/E ratio is a useful way to relate what you pay for the stock to the earnings the business is currently generating. Investors usually accept a higher P/E when they expect stronger earnings growth or see lower risk, and a lower P/E when growth prospects are more modest or risks are higher.

Thermo Fisher Scientific is trading on a P/E of about 25.67x. This sits below the Life Sciences industry average P/E of roughly 37.33x and also below the peer group average of about 41.67x. This signals the market is currently applying a lower earnings multiple than many comparable stocks.

Simply Wall St’s Fair Ratio for Thermo Fisher Scientific is 26.36x. This is a proprietary estimate of what a more suitable P/E might be given the company’s earnings growth profile, industry, profit margins, market cap and risk characteristics. Because it incorporates company specific factors rather than only broad peer or industry comparisons, it can provide a more tailored view of what investors might consider a reasonable multiple.

Comparing the Fair Ratio of 26.36x with the current P/E of 25.67x suggests the stock is trading below this Fair Ratio based estimate.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Thermo Fisher Scientific Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a simple way to link your view of Thermo Fisher Scientific’s story to a set of revenue, earnings and margin assumptions, and then to a fair value that you can compare with the current share price.

On Simply Wall St’s Community page, Narratives let you pick or create a storyline for the company, tie that directly to a forecast and a fair value estimate, and then see whether that fair value sits above or below today’s market price, which can help you decide whether the stock currently looks attractive, fully valued or expensive for your portfolio.

Because Narratives update as new information such as news, earnings or revised analyst models feed into the platform, you are not locked into a static view and can easily see how the story and the implied fair value change over time as conditions evolve.

For Thermo Fisher Scientific, for example, one investor might align with a bullish Narrative with a fair value around US$738.42, while another might prefer a more cautious Narrative closer to US$520.00. Comparing each of those to the current share price can lead to very different views about whether the stock appears attractive at the moment.

Do you think there's more to the story for Thermo Fisher Scientific? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.